EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pristine+™ Everolimus-Eluting Cobalt-Chromium Coronary Stent System: A Prospective, Multicenter Registry

Rishi Sethi, Akshyaya Pradhan, Pravesh Vishwakarma, Prakash Kumar Hazra, Sumanta Chatterjee, Supratip Kundu, Pradip Bhowmik, Parijat Deb Choudhury, Pranav Shamraj, Monika Bhandari, Sridhar Kasturi, Shanivaram Vijay Kumar Reddy und 5 weitere

Cardiology Research · 2026-08 · 17 (4) · 308-320

DOI: 10.14740/cr2230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiology Research, 2026-08. Verfasst von Rishi Sethi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recent advances in percutaneous coronary interventions (PCIs) have substantially improved clinical outcomes. Generating real-world evidence on the 1-year outcomes of ultrathin-strut drug-eluting stents (DES) remains important, particularly in healthcare settings where cost and accessibility may influence stent selection.

Methods

A prospective, single-arm, multicenter registry was conducted to evaluate the 1-year safety and efficacy of an indigenous everolimus-eluting cobalt–chromium stent (EES) (Pristine+™ - Make: Relisys Medical Devices Limited, India) featuring an ultrathin strut (60-µm) design. The primary endpoint was the 1-year incidence of major adverse cardiac event (MACE) defined as a composite of cardiac death (CD), myocardial infarction (MI), and stent thrombosis (ST).

Results

The study enrolled 1,088 patients, predominantly male (78.9%). High prevalence of diabetes mellitus (34.7%), hypertension (63.9%), and smoking history (25.7%) was noted. The mean age was 58.6 ± 10.6 years, with 69.9% between 36 and 65 years. A total of 95.9% completed the 1-year follow-up. At 1-year, the Kaplan–Meier incidence of MACE was 2.89% (40 events), comprising 18 CD (1.65%), 13 MI (1.19%), and nine ST (0.83%). All-cause mortality was 2.3% (25 events). One target-vessel myocardial infarction (TV-MI; 0.09%) was reported and no clinically indicated target-lesion revascularization (CI-TLR) events occurred.

Conclusion

This study demonstrated favorable 1-year clinical outcomes with Pristine+™, reflected by low rates of MACE and no CI-TLR during the 1-year follow-up. A total of 1,386 Pristine+ EES were implanted in this study.

Schlagwörter

Stichwörter der Autor:innen

Drug-eluting stentEverolimusPCIPristine+™Ultrathin strut

Autor:innen und Institutionen

  • Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India.
  • Department of Cardiology, Manipal Hospitals - Dhakuria, Kolkata, West Bengal, India.
  • Department of Cardiology, Manipal Hospitals - Mukundapur, Kolkata, West Bengal, India.
  • Department of Cardiology, B.K.L. Walawalkar Hospital, Chiplun, Maharashtra, India.
  • Department of Cardiac Sciences, KIMS Sunshine Hospitals, Hyderabad, Telangana, India.
  • Department of Cardiology, Jubilee Memorial Hospital, Thiruvananthapuram, Kerala, India.

Zitieren

APA

Sethi, R., Pradhan, A., Vishwakarma, P., Hazra, P. K., Chatterjee, S., Kundu, S., Bhowmik, P., Choudhury, P. D., Shamraj, P., Bhandari, M., Kasturi, S., Reddy, S. V. K., George, S., Sharma, Y. P., Panda, P. K., Potdar, A., & Patnaik, R. K. (2026). Pristine+™ Everolimus-Eluting Cobalt-Chromium Coronary Stent System: A Prospective, Multicenter Registry. Cardiology Research, 17(4), 308-320. https://doi.org/10.14740/cr2230

Vancouver

Sethi R, Pradhan A, Vishwakarma P, Hazra PK, Chatterjee S, Kundu S, et al. Pristine+™ Everolimus-Eluting Cobalt-Chromium Coronary Stent System: A Prospective, Multicenter Registry. Cardiology Research. 2026;17(4):308-320. doi:10.14740/cr2230

BibTeX
@article{Sethi2026,
  author = {Sethi, Rishi and Pradhan, Akshyaya and Vishwakarma, Pravesh and Hazra, Prakash Kumar and Chatterjee, Sumanta and Kundu, Supratip and Bhowmik, Pradip and Choudhury, Parijat Deb and Shamraj, Pranav and Bhandari, Monika and Kasturi, Sridhar and Reddy, Shanivaram Vijay Kumar and George, Sheeba and Sharma, Yash Paul and Panda, Prashant Kumar and Potdar, Anil and Patnaik, Ravi Kumar},
  title = {Pristine+™ Everolimus-Eluting Cobalt-Chromium Coronary Stent System: A Prospective, Multicenter Registry},
  journal = {Cardiology Research},
  year = {2026},
  volume = {17},
  number = {4},
  pages = {308--320},
  doi = {10.14740/cr2230}
}
Kostenlos starten →